Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases

A technology for nervous system diseases and nerve damage, which can be used in nervous system diseases, cardiovascular system diseases, drug combinations, etc., and can solve problems such as the inability to effectively regulate pain, and the inability to repair nerve tissue damage.

Inactive Publication Date: 2012-04-18
DONG KOOK PHARMA CO LTD
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are many cases where there is no effect, and when the pain is severe or lasts for a long time, nerve block surgery is often performed
[0009] Currently, antiviral agents and anti-inflammatory and analgesic agents are mainly prescribed for the treatment of shingles, because they cannot actually repair the damaged nerve tissue that is the main cause of herpes zoster and postherpetic neuralgia. Function plays a role, so pain cannot be effectively regulated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Preparation of H-Z Cream

[0063] Put 15g of stearic acid into a 250mL beaker, melt it completely in a water bath at 80-85°C, add 75mL of purified water to another 200mL beaker, dissolve 0.7g of potassium hydroxide and 10mL of glycerin, and heat it to the solution at 80-85°C, stirred, and then cooled to normal temperature to prepare vanishing cream.

[0064] In 229.0 g of aloe vera gel, add 100.7 g of the above-prepared cream, stir well, and then slowly add 16.03 g of ORONIA soybean lecithin (provided by Terrako Natural Source Company Ltd.) as a phospholipid or a sphingosine derivative , 1.60g α-tocopherol and 0.50g propyl benzoate (propyl benzoate), while stirring, prepare beige cream. At this time, the prepared composition contained 1.7% by weight of phospholipids or sphingosine derivatives.

Embodiment 2

[0065] Preparation of H-Z Cream

[0066] In 200.0g aloe vera gel, add 4.00g polysorbate #80, stir well, then slowly add 20.00g ORONIA soybean lecithin (supplied company: Terrako Natural Source Company Ltd.), 2.00g α-tocopherol and 0.30 g of propyl benzoate was stirred to prepare a beige cream. At this time, the prepared composition contained 3.24% by weight of phospholipids or sphingosine derivatives.

Embodiment 3

[0067] Preparation of H-Z Cream

[0068] Add 14.00 g of polysorbate #80 to 127.0 g of aloe vera gel, stir well, and then slowly add 70.00 g of GL-90E (provided by: Goshenbiotech Inc.), 7.00 g of phospholipids or sphingosine derivatives α-tocopherol and 0.30 g of propyl benzoate were stirred to prepare a beige cream. At this time, the prepared composition contained 29.1% by weight of phospholipids or sphingosine derivatives.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof. The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia.; Further, the pharmaceutical composition can be effectively used for neuronal damage, including sciatic nerve crushing damage or the like, in a neuropathy including diabetic neuropathy or the like and for neuropathic pain, as well as for a variety of diseases caused by nerve tissue damage, such as brain diseases including strokes or the like.

Description

technical field [0001] The present invention relates to a pharmaceutical composition capable of effectively treating nerve damage such as peripheral nerve damage, central nerve damage, and nervous system diseases such as neuropathy, neuropathic pain or brain disease by rapidly repairing damaged nerve tissue. Background technique [0002] Typically, Parkinson's disease, Alzheimer's disease, Huntington chorea, Spinocerebellar degeneration, amyotrophic lateral sclerosis, polyneuropathy, Many neurological diseases, such as spinal cord injury and cerebrovascular disorders, are caused by age, environment, genetics and other factors that cause degeneration, reduction, cell death, injury, and removal of brain or peripheral nerve cells. Therefore, in the treatment of such neurological diseases, it is important to replenish neurotransmitters lost due to damage of nerve cells, or to regenerate nerve cells. Methods for regenerating nerve cells include undifferentiated neural stem cells...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/688A61P25/28A61P25/16A61P25/00A61P35/00
CPCA61K9/107A61K9/0014A61K31/685A61K31/688A61K31/661A61K36/886A61P25/00A61P25/02A61P25/04A61P25/08A61P25/14A61P25/16A61P25/28A61P29/00A61P31/22A61P35/00A61P9/00A61P9/10A61P3/10
Inventor 郑在勋文炯荣
Owner DONG KOOK PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap